Date: 2014-12-18
Type of information: Series C financing round
Company: Nutrinia (Israel)
Investors: OrbiMed (USA - NY) Jacobs Investment Company (USA - FL) Pontifax (Israel)
Amount: $12 million
Funding type: series C financing round
Planned used: The funds will be used to advance two multinational clinical studies to support registration of NTRA-2112 for treating pre-term infants and NTRA-9620 for treating Short Bowel Syndrome in the EU and the United States. Nutrinia’s drugs are based on insulin, which has been shown to support the maturation and rehabilitation of the gastrointestinal tract. In four separate clinical studies, Nutrinia’s insulin formulation in oral presentation was shown to expedite GI maturity and growth, and improve several other clinical and economic parameters.
Others: * On December 18, 2014, Nutrinia, a leader in developing oral insulin therapies to treat rare gastrointestinal disorders in babies, announced the successful completion of a $12 million round of funding. The C round of financing was led jointly by internationally renowned investors OrbiMed, Jacobs Investment Company and Pontifax.
Therapeutic area: Rare diseases - Gastrointestinal diseases - Digestive diseases
